DILOXANIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H9Cl2NO2
Molecular Weight	234.079
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C(=O)C(Cl)Cl)C1=CC=C(O)C=C1

InChI

InChIKey=GZZZSOOGQLOEOB-UHFFFAOYSA-N

InChI=1S/C9H9Cl2NO2/c1-12(9(14)8(10)11)6-2-4-7(13)5-3-6/h2-5,8,13H,1H3

HIDE SMILES / InChI

Molecular Formula	C9H9Cl2NO2
Molecular Weight	234.079
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.fda.gov/ohrms/dockets/dockets/98n0182/nom003b.pdf

Diloxanide (used in the form of furoate) was developed for the treatment of intestinal amoebiasis. The effectiveness of the drug was proved in clinical trials, however, the mechanism of its action is unknown. The drug is not marketed in the United States, athough it is available in India.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Amebiasis 11 Sources: http://www.tm.mahidol.ac.th/pediatrics/sites/default/files/Antiparasitic-drugs.pdf	Curative		Approved 8583	DILOXANIDE FUROATE Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
activator 150 inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BCRP 910 CYP2C19 2057 CYP1A2 2153 P-gp 1741 UMAT 30 CYP19A1 429

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/885#sid=11112544	inconclusive [EC50 15.8489 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671197#sid=170466783	inconclusive [IC50 9.7717 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/884#sid=11112544	no [IC50 15.8489 uM]
BCRP 985	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1325#sid=855852	no
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/743139#sid=144207041	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/410#sid=11112544	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/891#sid=11112544	no
MRP1 232	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/799#sid=855852	no
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1326#sid=855852	no
UMAT 30	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/588550#sid=855852	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671198#sid=170466783	yes [IC50 15.4871 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671200#sid=170466783

PubMed

Title	Date	PubMed
Difficulties in the treatment of intestinal amoebiasis in mentally disabled individuals at a rehabilitation institution for the intellectually impaired in Japan.	2010	20720419
RPLC Determination of Tinidazole and Diloxanide Furoate in Tablets.	2008-09	21394273
Invasive amoebiasis complicating iflammatory bowel disease.	2007-12-01	21503247
Stability studies on diloxanide furoate: effect of pH, temperature, gastric and intestinal fluids.	2004-04	15081350

Patents

Sample Use Guides

In Vivo Use Guide

500mg 3 times daily for 5 days or 20mg/kg/daily divided into 3 daily doses for 10 days.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:33:21 GMT 2025` Edited by `admin` on `Wed Apr 02 08:33:21 GMT 2025`
Record UNII	89134SCM7M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DILOXANIDE

Official Name

English

DILOXANIDE [MI]

Preferred Name

English

Diloxanide [WHO-DD]

Common Name

English

diloxanide [INN]

Common Name

English

2,2-DICHLORO-4'-HYDROXY-N-METHYLACETANILIDE

Systematic Name

English

Classification Tree Code System Code

WHO-ESSENTIAL MEDICINES LIST

6.5.1